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Abstract. Peripheral neuropathy is a common complication of arsenic toxicity. Symptoms are 
usually mild and reversible following discontinuation of treatment. A more severe chronic 
sensorimotor polyneuropathy characterized by distal axonal-loss neuropathy can be seen in 
chronic arsenic exposure. The clinical course of arsenic neurotoxicity in patients with coexistence 
of thiamine deficiency is only anecdotally known but this association may potentially lead to 
severe consequences. 
We describe a case of acute irreversible axonal neuropathy in a patient with hidden thiamine 
deficiency who was treated with a short course of arsenic trioxide for acute promyelocytic 
leukemia. Thiamine replacement therapy and arsenic trioxide discontinuation were not followed 
by neurological recovery and severe polyneuropathy persisted at 12-month follow-up.  
Thiamine plasma levels should be measured in patients who are candidate to arsenic trioxide 
therapy. Prophylactic administration of vitamin B1 may be advisable. The appearance of 
polyneuropathy signs early during the administration of arsenic trioxide should prompt 
electrodiagnostic testing to rule out a pattern of axonal neuropathy which would need immediate 
discontinuation of arsenic trioxide.    
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Case report. 
Although polyneuropathy is common following 
arsenic trioxide therapy of subjects with acute 
promyelocytic leukemia (APL), symptoms are 
generally mild and they disappear after completion of 
arsenic treatment. In November 2014, a 72-year old 
Caucasian woman was admitted to this Unit with fever 
and pancytopenia (white blood cell count 0.19 x 10
9
/L, 
hemoglobin 76 g/L, platelets 41 x10
9
/L). She had a 
medical history of lobular carcinoma of the left breast 
treated with mastectomy and chemotherapy in 2012, 
Hashimoto thyroiditis, arterial hypertension. There was 
no prior neurological disorder and physical 
examination was unremarkable. Coagulation tests 
showed reduced prothrombin time ratio (59%) and 
normal activated partial thromboplastin time, a slightly 
reduced fibrinogen (1,4 g/L) and increased D-dimer 
(8634 g/L). Bone marrow evaluation was consistent 
with acute promyelocytic leukemia (APL) according to 
French-American-British (FAB) classification system. 
The patient was started on all-trans retinoic acid (45 
mg/m
2
) according to protocol APL0406
1
 and, by day 3, 
arsenic trioxide (ATO) 10 mg/d was added at the time 
of PML/RAR alpha rearrangement identification by 
PCR. The clinical course was complicated by 
differentiation syndrome, which manifested as mild 
increase of creatinine levels, peripheral edema and 
pleuro-pericardial effusion. All-trans retinoic acid was 
therefore stopped on day 12, dexamethasone and 
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furosemide added and the patient was continued on 
arsenic trioxide. 
On day 16, the patient gradually regained kidney 
function and all-trans retinoic was resumed. Starting on 
day 22, progressive cognitive impairment, insomnia, 
slurred speech, spatial and temporal disorientation 
occurred. As this worsening clinical picture was 
concomitant to hypernatremia (up to 160 mmol/L, 
reference values 136-145 mmol/L), neurological 
symptoms were attributed to sodium-related 
hyperosmolarity.  
Over the following days an impaired level of 
consciousness and lethargy was noticed. Progressive 
and appropriate normalization of natriemia did not 
improve neurological dysfunction.  
Additional diagnostic procedures were performed. 
A CT scan of the brain did not reveal abnormalities 
related to the acute clinical picture, showing only age-
related mild cerebral and cerebellar atrophy. 
Cerebrospinal fluid showed only mild protein 
elevation.    
Plasma levels of vitamin B1 were low (22 nmol/L, 
reference values 66-200 nmol/L) and supplementation 
was started. Over the following 5 days the patient 
showed a slow but progressive full recovery of 
cognitive functions.  
Unexpectedly, at normalization of cognitive 
function, a pattern of symmetric peripheral neuropathy 
involving upper and lower limbs became clinically 
evident. Physical examination showed that left and 
right hands were severely weak, particularly the 
abductor pollicis brevis, with mild strength reduction in 
the proximal arms. Deep-tendon reflexes were absent. 
There was bilateral foot drop, and the patient was 
unable to walk. Strength in the ankle dorsiflexors, 
extensor hallucis longus, extensor digitorum brevis, 
and toe flexors was severely compromised. There was 
no muscle atrophy or fasciculation, and the remainder 
of the neurologic examination was normal. 
Electromyography (EMG) showed a severe sensory-
motor axonal neuropathy of the upper and lower 
extremities with a greater reduction of sensory action 
potential.  
Meanwhile on day 28 arsenic trioxide had been 
stopped according to the therapy protocol. Bone 
marrow evaluation showed molecular remission. At 
that time the patient was bedridden because of a severe 
neurological impairment, so we chose not to administer 
consolidation therapy as it would have been required 
according to standard protocol.
1
 The patient was then 
continued on maintenance therapy with methotrexate 
and 6-mercaptopurine. Molecular remission was 
confirmed in bone marrow aspirate at the 13-month 
follow-up.  
Over the following on 6 months from arsenic 
trioxide discontinuation, the patient regained full 
proximal muscle strength but with almost complete 
persistence of marked distal weakness of the hands,ly 
finger and wrist extensors, weakness of foot 
dorsiflexors bilaterally and the inability to maintain an 
upright position. Neurological examination and EMG 
were substantially unchanged at the 12-month follow-
up evaluation. 
We believe that occult thiamine deficiency 
exacerbated arsenic trioxide neurotoxicity causing an 
unexpected and irreversible distal axonal symmetric 
neuropathy. This is the first report of acute and 
irreversible axonal neuropathy in a patient treated with 
arsenic trioxide with a background of thiamine 
deficiency. Peripheral neuropathy has long since been 
associated with the use of arsenic. Several clinical 
studies have been published on ATO treatment of 
patients with APL (Table).
2-12
 Although details on 
grade and duration of peripheral neuropathy were not 
always clearly included, overall grade 3/4 neuropathy 
accounts for about 0.5% of patients treated with ATO 
and recovery is always observed. Yip et al reported a 
case of severe neurotoxicity during arsenic therapy in a 
subject with APL and occult thiamine deficiency.
13
 
However, thiamine administration led to rapid 
improvement suggesting a major role of thiamine 
deficiency over arsenic toxicity.  
 
Table. Clinical studies reporting neurological adverse effects in APL patients treated with ATO 
 No. of cases 
All grade  
N° (%) 
Grade 3/4 
N° (%) 
Clinical course of neuropathy 
Soignet et al 2 12 3 (25) 0 - 
Niu et al 3 58 6 (10.3) 0 - 
Soignet et al 4 40 17 (42.5) 1 (2,5) FR 
Lazo et al 5 12 2 1 I 
Raffoux et al 6 20 2 0 - 
Shen et al 7 41 0 - - 
Shigeno et al 8 34 10 (29) 0 - 
Mathews et al 9 72 14 (19.4) 2 (2.7) I 
Estey et al 10 45 1 (2.2) NR NR 
Ghavamzadeh et al 11 197 0 - - 
Iland et al 12 124 9 (7.2) 9 (7.2) NR 
*Neurological side effects were dizziness, mood alteration, musculoskeletal pain, or seizure. Only 1 patient had grade 3 peripheral 
neuropathy during the induction phase. I: improved; FR: Full Recovery; NR: not reported 
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Severe and irreversible arsenic neurotoxicity in the 
setting of thiamine deficiency can be explained by their 
common metabolic target. In fact, thiamine deficiency 
and arsenic exposure severely impair pyruvate 
dehydrogenase (PDH) activity, an enzyme responsible 
for converting glucose to energy in high yield. As 
neural tissues are highly dependent on carbohydrates 
for energy production and cellular metabolism, it is 
tempting to speculate a synergic detrimental 
neuropathic effect leading to the severe toxicity 
observed in our patient. Of interest, we found 
electrophysiological findings consistent with acute 
axonal dysfunction without pattern of demyelination. 
This type of damage is the classic electrophysiological 
and histopathological finding in beriberi neuropathy 
whereas arsenic axonal toxicity characteristically 
coexists with segmental demyelination.
14,15
 An acute 
pattern of axonal damage has been reported as a 
manifestation of arsenic poisoning but it has not been 
observed as a side effect of short term administration 
of arsenic trioxide at therapeutic dosage.
16
 Thus, 
arsenic trioxide therapy may lead to axonal loss 
through the exacerbation of the metabolic damage to 
the nerve tissue induced by thiamine deficiency. This 
may have relevance in considering prophylactic 
administration of thiamine to subjects undergoing 
arsenic trioxide therapy for APL, a clinical approach 
already adopted by others
7
 and supported by animal 
models of antioxidant properties of thiamine in arsenic 
treated animals.
17
 
In conclusion, occult thiamine deficiency may 
contribute to arsenic toxicity and the combination may 
cause irreversible axonal neuropathy which must be 
considered when monitoring APL patients on arsenic 
trioxide therapy. Prophylactic administration of 
thiamine may be considered in this setting. 
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